JP2017522346A5 - - Google Patents

Download PDF

Info

Publication number
JP2017522346A5
JP2017522346A5 JP2017505176A JP2017505176A JP2017522346A5 JP 2017522346 A5 JP2017522346 A5 JP 2017522346A5 JP 2017505176 A JP2017505176 A JP 2017505176A JP 2017505176 A JP2017505176 A JP 2017505176A JP 2017522346 A5 JP2017522346 A5 JP 2017522346A5
Authority
JP
Japan
Prior art keywords
methyl
hydroxy
quinolyl
unsubstituted
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017505176A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522346A (ja
JP6759514B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/067400 external-priority patent/WO2016016316A1/en
Publication of JP2017522346A publication Critical patent/JP2017522346A/ja
Publication of JP2017522346A5 publication Critical patent/JP2017522346A5/ja
Application granted granted Critical
Publication of JP6759514B2 publication Critical patent/JP6759514B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017505176A 2014-08-01 2015-07-29 ブロモドメインに対して活性な化合物 Active JP6759514B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1450919-4 2014-08-01
SE1450919 2014-08-01
PCT/EP2015/067400 WO2016016316A1 (en) 2014-08-01 2015-07-29 Compounds active towards bromodomains

Publications (3)

Publication Number Publication Date
JP2017522346A JP2017522346A (ja) 2017-08-10
JP2017522346A5 true JP2017522346A5 (enExample) 2019-09-26
JP6759514B2 JP6759514B2 (ja) 2020-09-23

Family

ID=53765198

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017505176A Active JP6759514B2 (ja) 2014-08-01 2015-07-29 ブロモドメインに対して活性な化合物

Country Status (19)

Country Link
US (1) US10752640B2 (enExample)
EP (1) EP3174868B1 (enExample)
JP (1) JP6759514B2 (enExample)
KR (2) KR102633122B1 (enExample)
CN (1) CN106573915B (enExample)
AU (1) AU2015295405B2 (enExample)
CA (1) CA2956871C (enExample)
CL (1) CL2017000240A1 (enExample)
CO (1) CO2017001994A2 (enExample)
DK (1) DK3174868T3 (enExample)
ES (1) ES2896400T3 (enExample)
IL (1) IL250320B (enExample)
MA (1) MA40551A (enExample)
MX (1) MX378273B (enExample)
MY (1) MY187540A (enExample)
RU (1) RU2743074C2 (enExample)
SG (2) SG11201700776XA (enExample)
WO (1) WO2016016316A1 (enExample)
ZA (1) ZA201700670B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2990403A1 (en) * 2014-08-29 2016-03-02 Novartis Tiergesundheit AG Anthranilamides, sulfonamides and nitro analogues derived therefrom as anthelmintics
CA2992698A1 (en) 2015-07-17 2017-01-26 Toyama Chemical Co., Ltd. Nitrogen-containing heterocyclic compound
CN109153647A (zh) * 2016-02-15 2019-01-04 分子医学研究中心责任有限公司 用于治疗癌症的taf1抑制剂
JP6954921B2 (ja) * 2016-04-07 2021-10-27 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited ブロモドメイン阻害薬としてのピリジル誘導体
KR102598895B1 (ko) 2016-07-12 2023-11-07 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
WO2018075908A1 (en) * 2016-10-21 2018-04-26 University Of Miami Materials and methods for treating ophthalmic inflammation
EP3563851B1 (en) * 2016-12-27 2021-04-21 FUJIFILM Corporation Antitumor agent and bromodomain inhibitor
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ,インコーポレイテッド アロステリックshp2阻害剤としての二環式化合物
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
WO2018145620A1 (en) * 2017-02-07 2018-08-16 Janssen Pharmaceutica Nv Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis
WO2019001420A1 (en) 2017-06-27 2019-01-03 Janssen Pharmaceutica Nv HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING INFECTIONS WITH HEPATITIS B VIRUS
MX2020003579A (es) 2017-10-12 2020-07-22 Revolution Medicines Inc Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos.
TW201927791A (zh) 2017-12-15 2019-07-16 美商銳新醫藥公司 作為變構shp2抑制劑的多環化合物
EP3750885A4 (en) * 2018-02-06 2021-10-27 Shanghai Haihe Pharmaceutical Co., Ltd. COMPOUND PRESENTING AN INHIBITORING ACTIVITY OF BET, ITS PREPARATION PROCESS AND ITS USE
WO2019201291A1 (zh) * 2018-04-20 2019-10-24 中国科学院上海药物研究所 组蛋白乙酰转移酶(hat)抑制剂及其用途
CN109053542A (zh) * 2018-07-25 2018-12-21 南通大学 一种6-溴-5-羟基异吲哚啉-1-酮的化学合成方法
CA3107120A1 (en) 2018-07-31 2020-02-06 The Trustees Of Princeton University Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers
US11053235B2 (en) 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
EP3873893A1 (en) 2018-11-02 2021-09-08 Merck Sharp & Dohme Corp. 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
MA54550A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
MA54546A (fr) 2018-12-20 2022-03-30 Amgen Inc Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
AU2019401495B2 (en) 2018-12-20 2025-06-26 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
TWI827785B (zh) 2019-01-11 2024-01-01 德商歌林達有限公司 經取代的吡咯啶醯胺iii
CN114391012B (zh) * 2019-08-02 2025-10-31 美国安进公司 作为kif18a抑制剂的吡啶衍生物
ES3051918T3 (en) 2019-08-02 2025-12-30 Amgen Inc Kif18a inhibitors
AU2019462140A1 (en) * 2019-08-21 2022-02-24 Kalvista Pharmaceuticals Limited Enzyme inhibitors
JP2023511472A (ja) * 2019-10-29 2023-03-20 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための二官能性化合物
GB201918587D0 (en) * 2019-12-17 2020-01-29 Artios Pharma Ltd Novel compounds
IL294705A (en) * 2020-01-24 2022-09-01 Univ Princeton Heterocyclic compounds and their uses
EP4244213A4 (en) * 2020-11-10 2024-11-20 Foghorn Therapeutics Inc. COMPOUNDS AND USES THEREOF
GB202019475D0 (en) * 2020-12-10 2021-01-27 Cancer Research Tech Ltd Therapeutic compounds and their use
WO2022159445A1 (en) * 2021-01-19 2022-07-28 Metrea Biosciences, Inc. Compounds and methods of activating lipoprotein lipase
WO2022222890A1 (en) * 2021-04-19 2022-10-27 Shanghai Yao Yuan Biotechnology Co., Ltd. Benzothiazole and quinoline derivatives for use in treating kawasaki disease
JP7781391B2 (ja) * 2021-04-22 2025-12-08 カヨセラ インコーポレイテッド 複素環式化合物及びその使用
US12527741B2 (en) 2021-06-17 2026-01-20 Wisconsin Alumni Research Foundation Modular dendron micelles for treatment of pulmonary diseases related to fibrosis and viral infection including COVID-19
WO2023274418A1 (zh) * 2021-07-02 2023-01-05 南京明德新药研发有限公司 蛋白降解靶向嵌合体类化合物
MX2024001155A (es) * 2021-07-30 2024-07-01 Confo Therapeutics N V Compuestos para el tratamiento del dolor, en particular el dolor neuropatico, y/u otras enfermedades o trastornos que se asocian con at2r y/o se?alizacion mediada por at2r.
CN119365455A (zh) 2022-04-19 2025-01-24 纽韦卢森公司 对溴结构域有活性的化合物
US20250270200A1 (en) * 2022-04-21 2025-08-28 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof
CA3252955A1 (en) 2022-05-11 2023-11-16 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
CN119486735A (zh) * 2022-06-24 2025-02-18 载度思生命科学有限公司 用于肾小球疾病的治疗
CN119768400A (zh) * 2022-11-11 2025-04-04 苏州信诺维医药科技股份有限公司 一种稠环化合物、其用途及含其的药物组合物

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5328935B2 (enExample) 1972-01-20 1978-08-17
JPS56104333A (en) * 1980-01-23 1981-08-20 Fuji Photo Film Co Ltd Color photographic sensitive material
DE3445669A1 (de) 1984-12-14 1986-06-19 Boehringer Mannheim Gmbh, 6800 Mannheim Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPS6232459A (ja) 1985-08-05 1987-02-12 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
JPS6238463A (ja) 1985-08-14 1987-02-19 Fuji Photo Film Co Ltd ハロゲン化銀カラ−感光材料の画像形成方法
JPH067250B2 (ja) 1985-10-18 1994-01-26 富士写真フイルム株式会社 ハロゲン化銀カラ−写真感光材料
JPS6292939A (ja) 1985-10-19 1987-04-28 Fuji Photo Film Co Ltd 熱現像感光材料
JPH0756566B2 (ja) 1985-11-06 1995-06-14 富士写真フイルム株式会社 ハロゲン化銀カラ−写真感光材料の処理方法
JPS62129853A (ja) 1985-11-30 1987-06-12 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
JPS62153953A (ja) 1985-12-27 1987-07-08 Fuji Photo Film Co Ltd カラ−写真感光材料
JPS62173466A (ja) 1986-01-28 1987-07-30 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
JPS62222251A (ja) 1986-02-17 1987-09-30 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料の処理方法
JPS62257158A (ja) 1986-04-30 1987-11-09 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
DE3788600T2 (de) 1986-07-22 1994-04-28 Fuji Photo Film Co Ltd Verfahren zur Behandlung eines farbphotographischen Silberhalogenidmaterials.
DE3803775A1 (de) 1988-02-09 1989-08-17 Boehringer Mannheim Gmbh Neue substituierte lactame, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
JPH02234158A (ja) 1989-03-07 1990-09-17 Fuji Photo Film Co Ltd カラー感光材料
JPH02264946A (ja) 1989-04-05 1990-10-29 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
JPH02267548A (ja) 1989-04-10 1990-11-01 Fuji Photo Film Co Ltd 画像形成法
DE3925584A1 (de) 1989-08-02 1991-02-07 Boehringer Mannheim Gmbh Neue n-(dimethyloxophosphinylmethyl-)-lactame, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4027592A1 (de) 1990-08-31 1992-03-05 Beiersdorf Ag Neue pyrrolobenzimidazole, imidazobenzoxazinone und imidazochinolone, verfahren zu ihrer herstellung und ihre verwendung sowie die verbindungen enthaltende zubereitungen
JPH04315148A (ja) 1991-04-15 1992-11-06 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
GB9205702D0 (en) 1992-03-16 1992-04-29 Fujisawa Pharmaceutical Co A new use of a quinazoline derivative
EP0598216B1 (en) 1992-10-15 1997-04-23 Fuji Photo Film Co., Ltd. Method for processing silver halide color photographic material
JPH10501222A (ja) 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
US5756502A (en) 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
TW381092B (en) * 1995-07-07 2000-02-01 Otsuka Pharma Co Ltd Novel benzimidazole derivatives for use in treating arteriosclerotic diseases
US5747235A (en) 1996-01-26 1998-05-05 Eastman Kodak Company Silver halide light sensitive emulsion layer having enhanced photographic sensitivity
CA2246756A1 (en) 1996-02-28 1997-09-04 Merck & Co., Inc. Fibrinogen receptor antagonists
US5780480A (en) 1996-02-28 1998-07-14 Merck & Co., Inc. Fibrinogen receptor antagonists
EP1003374A4 (en) 1996-12-30 2000-05-31 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
JP2002508366A (ja) 1997-12-12 2002-03-19 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー キノリンピペラジンおよびキノリンピペリジン誘導体、それらの製造方法、ならびに複合的5−ht1a、5−ht1bおよび5−ht1d受容体アンタゴニストとしてのそれらの用途
EP1449834A3 (en) 1997-12-22 2004-12-22 Bayer Corporation Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
DE19839499A1 (de) 1998-08-29 2000-03-02 Merck Patent Gmbh 2-Oxo-2H-chinolinderivate
US6777413B2 (en) 2000-02-01 2004-08-17 Millennium Pharmaceuticals, Inc. 2-[1H]-quinolone and 2-[1H]-quinoxalone inhibitors of factor Xa
JP2002341484A (ja) 2001-03-12 2002-11-27 Fuji Photo Film Co Ltd 熱現像感光材料
JP2002296731A (ja) 2001-03-30 2002-10-09 Fuji Photo Film Co Ltd 熱現像カラー画像記録材料
WO2002090347A1 (en) 2001-04-30 2002-11-14 Fujisawa Pharmaceutical Co., Ltd. Amide compounds
EP1387612A1 (en) 2001-05-15 2004-02-11 E.I. Du Pont De Nemours And Company Pyridinyl fused bicyclic amide as fungicides
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Grk阻害剤
EP1388342A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
BR0313743A (pt) 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US7563807B2 (en) 2002-09-17 2009-07-21 Merck & Co. Inc. Removal of aldehyde impurity by reactive polystyrene resini
EP1572212A2 (en) 2002-12-11 2005-09-14 7TM Pharma A/S Quinoline compounds for use in mch receptor related disorders
US20040142950A1 (en) 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
EP1628666B1 (en) 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
BRPI0410746A (pt) 2003-05-19 2006-06-27 Irm Llc compostos e composições imunossupressoras
WO2005047244A2 (en) 2003-11-07 2005-05-26 Chiron Corporation Inhibition of fgfr3 and treatment of multiple myeloma
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
WO2005094805A1 (ja) 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体
US7312335B2 (en) 2004-06-03 2007-12-25 Brandeis University Asymmetric Michael and Aldol additions using bifunctional cinchona-alkaloid-based catalysts
GB0416730D0 (en) 2004-07-27 2004-09-01 Novartis Ag Organic compounds
EP1655295A1 (en) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
UY29198A1 (es) 2004-11-09 2006-05-31 Cancer Rec Tech Ltd Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones
US20060281763A1 (en) 2005-03-25 2006-12-14 Axon Jonathan R Carboxamide inhibitors of TGFbeta
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
GB0509224D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity
WO2006130437A2 (en) 2005-05-27 2006-12-07 Brandeis University Asymmetric carbon-carbon-bond-forming reactions catalyzed by bifunctional cinchona alkaloids
AU2006292119A1 (en) 2005-09-23 2007-03-29 3M Innovative Properties Company Method for 1H-imidazo[4,5-c]pyridines and analogs thereof
US8658801B2 (en) 2006-02-16 2014-02-25 Syngenta Crop Protection, Llc Pesticides containing a bicyclic bisamide structure
GB0605689D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic compounds
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
CA2652417A1 (en) 2006-05-19 2008-04-24 Bayer Healthcare Ag Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
WO2008029152A2 (en) 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
WO2008040778A2 (en) 2006-10-04 2008-04-10 Tibotec Pharmaceuticals Ltd. Carboxamide 4-[(4-pyridyl)amino] pyrimidines for the treatment of hepatitis c
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
CA2676173A1 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
CA2680173A1 (en) * 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
JP2008280341A (ja) 2007-04-12 2008-11-20 Sumitomo Chemical Co Ltd ヒドラジド化合物およびその防除用途
WO2009020677A2 (en) 2007-04-27 2009-02-12 University Of Rochester Compositions and methods for inhibiting g protein signaling
EP2008658A1 (en) 2007-06-28 2008-12-31 Bayer Schering Pharma Aktiengesellschaft Synergistic combination of anthranilamide pyridinureas and benzamide derivatives
CN102746239B (zh) 2007-09-17 2016-02-10 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
EA201001847A1 (ru) 2008-06-11 2011-08-30 Айрм Ллк Соединения и композиции, применяемые для лечения малярии
WO2010030967A1 (en) 2008-09-12 2010-03-18 Wyeth Llc 4-aryloxyquinolin-2(1h)-ones as mtor kinase and pi3 kinase inhibitors, for use as anti-cancer agents
WO2010045374A1 (en) 2008-10-15 2010-04-22 Gilead Palo Alto, Inc. 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
SG172336A1 (en) 2008-12-23 2011-07-28 Hoffmann La Roche Dihydropyridone amides as p2x7 modulators
CN102414180A (zh) 2009-03-02 2012-04-11 西特里斯药业公司 作为沉默调节蛋白调节剂的8-取代的喹啉及相关的类似物
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
US8362249B2 (en) * 2009-04-27 2013-01-29 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
MY160456A (en) * 2009-11-05 2017-03-15 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
CA2797694A1 (en) 2010-04-29 2011-11-03 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Activators of human pyruvate kinase
ES2715611T3 (es) 2010-05-17 2019-06-05 Incozen Therapeutics Pvt Ltd Compuestos novedosos de 3H-imidazo[4,5-b]piridina-3,5-disustituida y 3H-[1,2,3]triazolo[4,5-b]piridina 3,5-disustituida como moduladores de proteína cinasas
WO2011156632A2 (en) 2010-06-09 2011-12-15 Georgetown University Compositions and methods of treatment for tumors in the nervous system
WO2012020820A1 (ja) 2010-08-11 2012-02-16 大正製薬株式会社 ヘテロアリール-ピラゾール誘導体
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
AR084280A1 (es) 2010-12-17 2013-05-02 Hoffmann La Roche Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos
TW201309639A (zh) 2011-02-17 2013-03-01 Lg Life Sciences Ltd 作為gpr119促效劑之肟衍生物
WO2012125668A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
GB201106750D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201106743D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
JP5742439B2 (ja) 2011-05-02 2015-07-01 信越化学工業株式会社 蛍光性化合物及び蛍光性樹脂組成物
DK2713722T3 (en) 2011-05-31 2017-07-03 Celgene Int Ii Sarl Newly known GLP-1 receptor stabilizers and modulators
CN102887895B (zh) 2011-07-22 2016-08-24 山东轩竹医药科技有限公司 吡啶并嘧啶类mTOR抑制剂
EP2736330A4 (en) 2011-07-29 2015-05-27 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
ES2699226T3 (es) * 2011-10-14 2019-02-08 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
WO2013063462A2 (en) 2011-10-26 2013-05-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of treating hcv infection with a small molecule chk2 inhibitor
IN2014MN01982A (enExample) 2012-04-25 2015-07-10 Raqualia Pharma Inc
JPWO2014034719A1 (ja) 2012-08-29 2016-08-08 興和株式会社 Tlr阻害作用を有するキノリン誘導体
EP2935260A1 (de) 2012-12-20 2015-10-28 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische dihydropyridopyrazinone
JP2016509576A (ja) 2012-12-20 2016-03-31 バイエル ファーマ アクチエンゲゼルシャフト Betタンパク質阻害性ジヒドロキノキザリノン類

Similar Documents

Publication Publication Date Title
JP2017522346A5 (enExample)
RU2017104510A (ru) Соединения, активные по отношению к бромодоменам
CN103121996B (zh) 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物
RU2573834C2 (ru) ФАРМАЦЕВТИЧЕСКИ АКТИВНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Axl
RU2018137194A (ru) Ингибиторы бромдомена
JP2015503529A5 (enExample)
TWI465439B (zh) 三氮唑衍生物或其鹽
JP7228586B2 (ja) キナーゼ阻害剤としてのアミノイミダゾピリダジン
JP2013510876A5 (enExample)
JP5462803B2 (ja) イミノピリジン誘導体およびその用途
JP2018512381A5 (enExample)
JP2007514690A (ja) ヒスタミンh3アンタゴニストとしてのベンズアゼピン誘導体
JP2017502057A (ja) ブロモドメイン阻害剤としての二環式複素環誘導体
CA2988637A1 (en) Aromatic sulfonamide derivatives
TW202118759A (zh) 用於治療癌症之1,2,4—二唑—5—酮衍生物
JP2010522770A5 (enExample)
JP2008509955A5 (enExample)
KR20230043103A (ko) 술폰아마이드 화합물
CN105102454A (zh) 作为cetp抑制剂的新型噁唑烷酮衍生物、其制备方法和包含其的药物组合物
CN111356695A (zh) 新的三环化合物
WO2025106780A1 (en) Rxfp1 receptor agonists
TW201245187A (en) Pyrazole derivatives
CN115109048B (zh) 一种(杂)芳基酰胺类化合物
WO2009131135A1 (ja) イミノピリジン誘導体およびその用途
CA2588457A1 (en) Triazole compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor